0RC7 Stock Chart & Stats
kr45.27
kr0.44(1.28%)
At close: 4:00 PM EDT
kr45.27
kr0.44(1.28%)
Day’s Range― - ―
52-Week Rangekr23.57 - kr48.00
Previous CloseN/A
Volume20.86K
Average Volume (3M)2.74K
Market Cap
kr3.89B
Enterprise Valuekr4.01B
Total Cash (Recent Filing)kr552.81M
Total Debt (Recent Filing)kr1.03B
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Nov 05, 2026EPS Estimate
6.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.86
Shares Outstanding101,763,220
10 Day Avg. Volume1,112
30 Day Avg. Volume2,744
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)-31.35
Price to Sales (P/S)12.55
P/FCF Ratio-5.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr103.00Price Target Upside127.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.03
Revenue Forecast (FY)kr467.54M
Bulls Say, Bears Say
Bulls Say
SERB Partnership Strengthens LiquidityThe SERB transaction provides substantial near-term funding and extends the company’s runway ahead of potential U.S. approval. It also validates the platform commercially, adds a regional commercialization partner, and can reduce financing pressure while Hansa advances its own pipeline.
Strong Confirmatory Clinical EfficacyPositive confirmatory data strengthens imlifidase’s clinical and regulatory foundation by demonstrating better kidney function and reduced dialysis dependence versus control. This supports European approval conversion, physician confidence, and the durability of the lead product’s commercial opportunity.
U.S. Launch And Regulatory ReadinessA defined U.S. regulatory milestone, active center preparation, and planned market-access work create a clear path toward geographic expansion. Approval could broaden Idefirix’s commercial reach beyond Europe and improve the company’s ability to scale revenue from a specialized transplant indication.
Bears Say
Sharp Revenue Decline And Deep LossesThe sharp TTM revenue contraction shows that the existing commercial base has not yet produced reliable scale. Extremely negative profitability means product-level gross margin is being outweighed by operating costs, leaving the business dependent on future growth, partnerships, or external funding.
Negative Equity And Persistent Cash BurnNegative equity combined with substantial debt reduces financial flexibility and increases sensitivity to continued losses. Persistent operating and free-cash-flow deficits indicate that the company is consuming cash to fund operations, making the recently strengthened liquidity important but not a complete solution.
Higher Antibody-mediated Rejection RateThe higher observed AMR rate remains a clinically meaningful consideration for physicians, regulators, and transplant centers even though management described events as manageable and reported no graft losses. Continued monitoring and treatment could complicate adoption and limit confidence in broader use.
Hansa Biopharma AB News
0RC7 FAQ
What was Hansa Biopharma AB’s price range in the past 12 months?
Hansa Biopharma AB lowest share price was kr23.57 and its highest was kr48.00 in the past 12 months.
What is Hansa Biopharma AB’s market cap?
Hansa Biopharma AB’s market cap is kr3.89B.
When is Hansa Biopharma AB’s upcoming earnings report date?
Hansa Biopharma AB’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
How were Hansa Biopharma AB’s earnings last quarter?
Hansa Biopharma AB released its earnings results on Jul 22, 2026. The company reported -kr2.56 earnings per share for the quarter, missing the consensus estimate of -kr0.337 by -kr2.223.
Is Hansa Biopharma AB overvalued?
According to Wall Street analysts Hansa Biopharma AB’s price is currently Undervalued.
Does Hansa Biopharma AB pay dividends?
Hansa Biopharma AB does not currently pay dividends.
What is Hansa Biopharma AB’s EPS estimate?
Hansa Biopharma AB’s EPS estimate is 6.12.
How many shares outstanding does Hansa Biopharma AB have?
Hansa Biopharma AB has 101,763,220 shares outstanding.
What happened to Hansa Biopharma AB’s price movement after its last earnings report?
Hansa Biopharma AB reported an EPS of -kr2.56 in its last earnings report, missing expectations of -kr0.337. Following the earnings report the stock price went up 0.395%.
Which hedge fund is a major shareholder of Hansa Biopharma AB?
Currently, no hedge funds are holding shares in GB:0RC7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hansa Biopharma AB
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.
0RC7 Stock 12 Month Forecast
Average Price Target
kr103.00
▲(127.52% Upside)
Technical Analysis
Alligator Bioscience AB
―
BioInvent International AB
―
SynAct Pharma AB
―
Xbrane Biopharma AB
―
Cantargia AB
―